QRX003, 4% Lotion
Phase 2/3Recruiting 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Netherton Syndrome
Conditions
Netherton Syndrome
Trial Timeline
Jul 1, 2025 → Jul 30, 2026
NCT ID
NCT06953466About QRX003, 4% Lotion
QRX003, 4% Lotion is a phase 2/3 stage product being developed by Quoin Pharmaceuticals for Netherton Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06953466. Target conditions include Netherton Syndrome.
Hype Score Breakdown
Clinical
15
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06953466 | Phase 2/3 | Recruiting |
| NCT05789056 | Phase 2/3 | Recruiting |
Competing Products
8 competing products in Netherton Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| DS-2325a | Daiichi Sankyo | Phase 1/2 | 24 |
| DS-2325a + DS-2325a + Placebo + Placebo | Daiichi Sankyo | Phase 1 | 29 |
| DS-2325a + Placebo | Daiichi Sankyo | Phase 1 | 29 |
| Pimecrolimus 1% Cream | Novartis | Phase 1/2 | 32 |
| BCX17725 + Placebo | BioCryst Pharmaceuticals | Phase 1 | 30 |
| QRX003-2% Lotion + QRX003-4% Lotion QAM + Vehicle + QRX003-4% Lotion BID | Quoin Pharmaceuticals | Phase 2/3 | 32 |
| QRX003, 4% Lotion | Quoin Pharmaceuticals | Phase 2/3 | 35 |
| ATR12-351 | Azitra | Phase 1 | 26 |